In the first half of 2026 Chinese innovative medicines have smashed through a $100 billion overseas licensing barrier, signalling a qualitative leap for the nation’s pharma sector. The National Medical Products Administration reported 38 Class‑1 innovative drugs approved – 20 chemicals, 17 biologics and one traditional formula – while outbound licensing deals reached a disclosed $99.7 billion, nearly double 2024’s total and about 73 % of 2025’s full‑year value. The shift is more than numbers. Companies are moving from one‑off sell‑outs of early‑stage assets to joint development, profit‑sharing and equity partnerships with multinational giants. Akeso’s home‑grown PD‑1/VEGF bispecific antibody ivonescimab doubled progression‑free survival versus pembrolizumab in a Phase III trial, and Kelun‑Biotech’s TROP2‑ADC sacituzumab tirumotecan earned global approval after a landmark Phase III study showed survival gains in endometrial cancer. China’s pipeline now boasts first‑in‑world products – a bispecific antibody ADC, a solid‑tumor CAR‑T, a hepatitis B/D monoclonal antibody and a novel radiopharmaceutical – underscoring a move from follow‑on to true original innovation. With outbound licensing transactions soaring from $51.9 billion in 2024 to $135.6 billion in 2025, the next battleground will be sustained creation of differentiated clinical value and building robust overseas commercialization capabilities.
Read more